Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Pelican Therapeutics (Future Milestone Payments) (Details)

v3.19.1
Acquisition of Pelican Therapeutics (Future Milestone Payments) (Details) - Pelican Therapeutics, Inc. [Member]
Mar. 31, 2019
USD ($)
Business Acquisition [Line Items]  
Future milestone payment upon Pelican's dosing of the first patient in its first Phase 1 trial for an oncology indication $ 2,000,000
Future milestone payment upon Pelican's dosing of the first patient in its first Phase 2 trial for an oncology indication 1,500,000
Future milestone payment upon successful outcome of the first Phase 2 trial for an oncology indication 3,000,000
Future milestone payment upon Pelican's dosing of the first patient in its first Phase 3 trial for an oncology indication 6,000,000
Future milestone payment upon Pelican's dosing of the first patient in its first Phase 3 trial for a non- oncology indication 3,000,000
Future milestone payment upon successful outcome of the first Phase 3 trial for an oncology indication 7,500,000
Future milestone payment upon successful outcome of the first Phase 3 trial for a non-oncology indication 3,000,000
Future milestone payment upon acceptance of a Biologics License Application (BLA) submission for an oncology indication 7,500,000
Future milestone payment upon acceptance of a BLA submission for a non-oncology indication 3,000,000
Future milestone payment upon first product indication approval in the United States or Europe for an oncology indication 7,500,000
Future milestone payment upon first product indication approval in the United States or Europe for a non- oncology indication $ 3,000,000
Discount rate used for calculation of fair value of contingent consideration 6.00%